Donanemab is administered every four weeks through IV infusion, with each infusion lasting about 30 minutes. Patients are monitored for a period of time, usually about 30 minutes, after each infusion to ensure there are no negative reactions to the drug. The number of infusions is dependent upon the patient: some may be able to stop treatment in as little as six months, while others could receive treatment for up to 12 or 18 months.